Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

Blood (2024) 143 (18): 1807–1815.

https://doi.org/10.1182/blood.2023022725

Published: 2024

Includes: Supplemental data

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Blood (2023) 142 (Supplement 1): 5394.

https://doi.org/10.1182/blood-2023-182876

Published: 2023

Journal Articles

Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-136627

Published: 2020

Journal Articles

Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group

Maria Cristina Pascual Izquierdo, PhD MD, Julio Del Rio-Garma, MD, Javier De La Rubia, Aurora Viejo, MD, Jesus Fernandez-Sojo, MD, Jesus Martin, MD, Xavier Solanich, MD, Faustino García-Candel, PhD MD, Luis Hernandez, MD, Marta Fernandez, MD, Ana Oliva, MD, Jose Maria Garcia-Gala, MD, Maria Eva Mingot-Castellano, PhD MD, Ines Gomez-Seguí, MD PhD, Rosa Goterris, MD, Michael Calviño, MD, María Luisa Antelo, MD PhD, Sol Sanchez, MD, Jose Antonio Moreno, MD, Cristina Amunarriz, MD, Jose Garcia-Arroba, MD, Carmen Fernandez, MD, Nieves Alonso, MD, Victoria Gonzalez, MD, Luisa Guerra, MD, M. Elena Moreno, MD, Moreno M. Dolores, MD, Gemma Moreno, MD, Melisa Daorta, MD, Esther Chica, MD, Rafael Del Orbe, MD PhD, Joan Cid, MD PhD, Margarita Berberana, MD, Carmen Ballester, MD, Sara Nistal Gil, MD, Julia Vidan, MD, Maite Calderon, MD, Consuelo Martinez Redondo, MD, Jose Carlos Hernandez, MD, Marina Gordillo, MD, Angel Salgado, Ramon Salinas, MD PhD

Blood (2019) 134 (Supplement_1): 4910.

https://doi.org/10.1182/blood-2019-123258

Published: 2019

Journal Articles

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry

Blood (2019) 134 (Supplement_1): 1082.

https://doi.org/10.1182/blood-2019-122665

Published: 2019

NARROW

ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry

Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry

Email alerts

ASH Publications

American Society of Hematology

ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Effect of Caplacizumab in the Recovery of ADAMTS13 Level in Patients with Autoimmune Thrombotic Thrombocytopenic Purpura. Analysis from the Spanish Registry (REPTT)

Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry

Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only